Financing activity during the third quarter reached $4.05bn, a 76% increase over Q2's $2.3bn total, with most (43%) of the Q3 dollars allocated to debt raises. (See Exhibit 1.) Insulet Corp., the maker of theOmnipod insulin management system, completed a private placement of $700m (net $684.3m) aggregate principal amount of convertible senior notes, the largest debt transaction and also the biggest financing deal of Q3 [See Deal].
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?